Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer

Muthusamy Thangaraju, Kalyanam Kumar, Rengasamy Gandhirajan, Panchanatham Sachdanandam

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Background. Adjuvant tamoxifen therapy is given to large and increasing numbers of women with early‐stage breast cancer. The effects of this drug on plasma lipids and lipoprotein profiles are important, because cardiovascular disease also develops over time in a large percentage of tamoxifen‐treated postmenopausal women. The purpose of the study was to evaluate the effects of tamoxifen on plasma lipid and lipoprotein profiles in postmenopausal Indian women who were disease‐free after primary treatment for breast cancer. Methods. A short‐term evaluation of 6 months of tamoxifen therapy (10 mg twice a day) in 45 postmenopausal women was conducted. The plasma lipids and lipoprotein levels were evaluated before and after 3 and 6 months of tamoxifen treatment. Results. At 3 and 6 months' evaluation, patients receiving tamoxifen showed significantly decreased levels of total cholesterol, free cholesterol, and low‐density lipoprotein cholesterol (P < 0.001 for each) and increased levels of plasma triglycerides, free fatty acids, very low density lipoprotein cholesterol, and high‐density lipoprotein cholesterol. Conclusion. The results suggest that tamoxifen therapy benefits postmenopausal patients with breast cancer, with likely reduction in the risk of cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)659-663
Number of pages5
JournalCancer
Volume73
Issue number3
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Tamoxifen
Lipoproteins
Breast Neoplasms
Lipids
Cardiovascular Diseases
Cholesterol
Therapeutics
VLDL Cholesterol
Risk Reduction Behavior
Nonesterified Fatty Acids
Triglycerides
Pharmaceutical Preparations

Keywords

  • breast cancer
  • cardiovascular disease
  • lipids
  • lipoproteins
  • postmenopausal women
  • tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. / Thangaraju, Muthusamy; Kumar, Kalyanam; Gandhirajan, Rengasamy; Sachdanandam, Panchanatham.

In: Cancer, Vol. 73, No. 3, 01.01.1994, p. 659-663.

Research output: Contribution to journalArticle

Thangaraju, Muthusamy ; Kumar, Kalyanam ; Gandhirajan, Rengasamy ; Sachdanandam, Panchanatham. / Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. In: Cancer. 1994 ; Vol. 73, No. 3. pp. 659-663.
@article{4e6d0c4206ba4334a84d6befd6722289,
title = "Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer",
abstract = "Background. Adjuvant tamoxifen therapy is given to large and increasing numbers of women with early‐stage breast cancer. The effects of this drug on plasma lipids and lipoprotein profiles are important, because cardiovascular disease also develops over time in a large percentage of tamoxifen‐treated postmenopausal women. The purpose of the study was to evaluate the effects of tamoxifen on plasma lipid and lipoprotein profiles in postmenopausal Indian women who were disease‐free after primary treatment for breast cancer. Methods. A short‐term evaluation of 6 months of tamoxifen therapy (10 mg twice a day) in 45 postmenopausal women was conducted. The plasma lipids and lipoprotein levels were evaluated before and after 3 and 6 months of tamoxifen treatment. Results. At 3 and 6 months' evaluation, patients receiving tamoxifen showed significantly decreased levels of total cholesterol, free cholesterol, and low‐density lipoprotein cholesterol (P < 0.001 for each) and increased levels of plasma triglycerides, free fatty acids, very low density lipoprotein cholesterol, and high‐density lipoprotein cholesterol. Conclusion. The results suggest that tamoxifen therapy benefits postmenopausal patients with breast cancer, with likely reduction in the risk of cardiovascular disease.",
keywords = "breast cancer, cardiovascular disease, lipids, lipoproteins, postmenopausal women, tamoxifen",
author = "Muthusamy Thangaraju and Kalyanam Kumar and Rengasamy Gandhirajan and Panchanatham Sachdanandam",
year = "1994",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19940201)73:3<659::AID-CNCR2820730325>3.0.CO;2-H",
language = "English (US)",
volume = "73",
pages = "659--663",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer

AU - Thangaraju, Muthusamy

AU - Kumar, Kalyanam

AU - Gandhirajan, Rengasamy

AU - Sachdanandam, Panchanatham

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Background. Adjuvant tamoxifen therapy is given to large and increasing numbers of women with early‐stage breast cancer. The effects of this drug on plasma lipids and lipoprotein profiles are important, because cardiovascular disease also develops over time in a large percentage of tamoxifen‐treated postmenopausal women. The purpose of the study was to evaluate the effects of tamoxifen on plasma lipid and lipoprotein profiles in postmenopausal Indian women who were disease‐free after primary treatment for breast cancer. Methods. A short‐term evaluation of 6 months of tamoxifen therapy (10 mg twice a day) in 45 postmenopausal women was conducted. The plasma lipids and lipoprotein levels were evaluated before and after 3 and 6 months of tamoxifen treatment. Results. At 3 and 6 months' evaluation, patients receiving tamoxifen showed significantly decreased levels of total cholesterol, free cholesterol, and low‐density lipoprotein cholesterol (P < 0.001 for each) and increased levels of plasma triglycerides, free fatty acids, very low density lipoprotein cholesterol, and high‐density lipoprotein cholesterol. Conclusion. The results suggest that tamoxifen therapy benefits postmenopausal patients with breast cancer, with likely reduction in the risk of cardiovascular disease.

AB - Background. Adjuvant tamoxifen therapy is given to large and increasing numbers of women with early‐stage breast cancer. The effects of this drug on plasma lipids and lipoprotein profiles are important, because cardiovascular disease also develops over time in a large percentage of tamoxifen‐treated postmenopausal women. The purpose of the study was to evaluate the effects of tamoxifen on plasma lipid and lipoprotein profiles in postmenopausal Indian women who were disease‐free after primary treatment for breast cancer. Methods. A short‐term evaluation of 6 months of tamoxifen therapy (10 mg twice a day) in 45 postmenopausal women was conducted. The plasma lipids and lipoprotein levels were evaluated before and after 3 and 6 months of tamoxifen treatment. Results. At 3 and 6 months' evaluation, patients receiving tamoxifen showed significantly decreased levels of total cholesterol, free cholesterol, and low‐density lipoprotein cholesterol (P < 0.001 for each) and increased levels of plasma triglycerides, free fatty acids, very low density lipoprotein cholesterol, and high‐density lipoprotein cholesterol. Conclusion. The results suggest that tamoxifen therapy benefits postmenopausal patients with breast cancer, with likely reduction in the risk of cardiovascular disease.

KW - breast cancer

KW - cardiovascular disease

KW - lipids

KW - lipoproteins

KW - postmenopausal women

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0027955643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027955643&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19940201)73:3<659::AID-CNCR2820730325>3.0.CO;2-H

DO - 10.1002/1097-0142(19940201)73:3<659::AID-CNCR2820730325>3.0.CO;2-H

M3 - Article

C2 - 8299087

AN - SCOPUS:0027955643

VL - 73

SP - 659

EP - 663

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -